Organisation
Pfizer/ BioNTech
Country
US/Germany
mRNA vaccine (it uses the virus
that causes colds in chimpanzees)
What type is it?
Probably available in limited
quantities by the end of 2020
When could it
be ready?
Organisation
Oxford University/ AstraZeneca
Country
UK
Adenovirus vector vaccine
(delivered using a chimp
cold virus)
What type is it?
Interim results due in weeks and,
if good, limited quantities could
be available by the end of 2020
When could it
be ready?
Organisation
Moderna
Country
US
mRNA vaccine
What type is it?
Interim data expected late
November. CEO has said it is
unlikely to be widely available
in the first quarter of 2021
When could it
be ready?
Organisation
Novavax
Country
US
Protein adjuvant vaccine
(boosts immune system)
What type is it?
If phase 3 trials, which include
100,000 UK volunteers, go well,
there may be doses available in
the second half of next year
When could it
be ready?
Organisation
Janssen Pharmaceuticals
(part of Johnson&Johnson)
Country
US
Adenovirus vector vaccine
What type is it?
In phase 3 trials and expected
to deliver in the second half of
next year if all goes well
When could it
be ready?
Organisation
Valneva
Country
France
Traditional approach with a
whole, inactivated virus
What type is it?
Doses to be manufactured in
Scotland and available in second
half of 2021 if safety and efficacy
data is good
When could it
be ready?
Organisation
Sinovac
Country
China
Traditional approach with a
whole, inactivated virus
What type is it?
In phase 3 trials in Brazil,
Indonesia and Turkey. Interim
data expected in November, but
Brazil trial now on pause because
of a side-effect issue. Has already
been offered for emergency
vaccination in the Chinese city of
Jiaxing
When could it
be ready?
Organisation
Country
What type is it?
When could it be ready?
Pfizer/ BioNTech
mRNA vaccine (using
genetic code of virus)
Probably available in limited
quantities by the end of 2020
US/Germany
Oxford University/
AstraZeneca
UK
Adenovirus vector vaccine
(it uses the virus that causes
colds in chimpanzees)
Interim results due in weeks and,
if good, limited quantities could
be available by the end of 2020
Moderna
US
mRNA vaccine
Interim data expected late
November. CEO has said it is
unlikely to be widely available
in the first quarter of 2021
Novavax
US
Protein adjuvant vaccine
(boosts immune system)
If phase 3 trials, which include
100,000 UK volunteers, go well,
there may be doses available in
the second half of next year
Janssen Pharmaceuticals
(part of Johnson&
Johnson)
US
Adenovirus vector vaccine
In phase 3 trials and expected
to deliver in the second half of
next year if all goes well
Valneva
France
Traditional approach with a
whole, inactivated virus
Doses to be manufactured in
Scotland and available in second
half of 2021 if safety and efficacy
data is good
Sinovac
China
Traditional approach with a
whole, inactivated virus
In phase 3 trials in Brazil,
Indonesia and Turkey. Interim
data expected in November, but
Brazil trial now on pause because
of a side-effect issue. Has already
been offered for emergency
vaccination in the Chinese city of
Jiaxing